Abbott Laboratories Analyst Price Targets - Benzinga

Abbott Laboratories

ABTNYSE

Trade with Public

Trade with Public

$97.50

0.810.84%

Últ. Act.: Oct 2, 7:54 PM

$97.51

0.820.85%

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Dividendos Comparar Opciones Informe de acciones

© 2026 Benzinga | All Rights Reserved

Abbott Laboratories Analyst Price Targets - Benzinga

Abbott Laboratories Analyst Price Targets

Wall Street analyst price targets and consensus rating for Abbott Laboratories (ABT).

Price Target Range — 9 Quarters

Analyst Consensus — 23 Analysts

22Buy

1Hold

Consensus RatingBuy# Analysts23Avg. Consensus PT$129Upside to Avg. PT+32.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 2, 2026	Rothschild & Co	Ed Ridley-Day	Upgrade	Neutral→Buy	$119→$127
Sep 8, 2026	TD Cowen	Joshua Jennings	Maintained	Buy	$135
Aug 21, 2026	TD Cowen	Joshua Jennings	PT Raise	Buy	$115→$135
Aug 14, 2026	Citigroup	Joanne Wuensch	PT Raise	Buy	$112→$125
Aug 13, 2026	Wolfe Research	Mike Polark	Upgrade	Peer Perform→Outperform	$130
Jul 28, 2026	UBS	Patrick Wood	PT Cut	Buy	$135→$125
Jul 17, 2026	Citigroup	Joanne Wuensch	PT Raise	Buy	$108→$112
Jul 17, 2026	Piper Sandler	Adam Maeder	PT Raise	Overweight	$115→$118
Jul 17, 2026	JP Morgan	Robbie Marcus	PT Raise	Overweight	$110→$120
Jul 17, 2026	Wells Fargo	Larry Biegelsen	PT Raise	Overweight	$109→$112
Jul 17, 2026	TD Cowen	Joshua Jennings	Maintained	Buy	$115
Jul 17, 2026	Evercore ISI Group	Vijay Kumar	PT Raise	Outperform	$112→$120
Jul 17, 2026	RBC Capital	Shagun Singh	Maintained	Outperform	$130
Jul 17, 2026	BTIG	Marie Thibault	PT Raise	Buy	$131→$134
Jul 6, 2026	Evercore ISI Group	Vijay Kumar	PT Cut	Outperform	$120→$112
Jul 1, 2026	Baird	David Rescott	Initiate	Outperform	$121
Jun 22, 2026	Piper Sandler	Adam Maeder	Maintained	Overweight	$115
May 31, 2026	Goldman Sachs	David Roman	PT Cut	Buy	$121→$113
Apr 27, 2026	BTIG	Marie Thibault	Maintained	Buy	$131
Apr 20, 2026	Barclays	Matt Miksic	PT Cut	Overweight	$144→$143

More with Benzinga EdgeGet Access

Analyst Ratings News

Abbott To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Friday

Analysts raised targets for ACN, SYNA, ATRC and MPC; cut targets for CSX, NKE, MKC and FHTX, with ATRC downgraded to Hold.

Avi Kapoor

This Hewlett Packard Enterprise Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Analysts upgraded HPE, Abbott, Airbnb, Horizon Bancorp and Triumph Financial, raising or setting price targets and issuing more bullish ratings.

Avi Kapoor

PRO
Rothschild & Co Upgrades Abbott Laboratories to Buy, Raises Price Target to $127

Rothschild & Co analyst Ed Ridley-Day upgrades Abbott Laboratories (NYSE:ABT) from Neutral to Buy and raises the price target from $119 to $127.

Benzinga Newsdesk

PRO
TD Cowen Reiterates Buy on Abbott Laboratories, Maintains $135 Price Target

TD Cowen analyst Joshua Jennings reiterates Abbott Laboratories (NYSE:ABT) with a Buy and maintains $135 price target.

Benzinga Newsdesk

PRO
Wolfe Research Upgrades Abbott Laboratories to Outperform, Announces $130 Price Target

Wolfe Research analyst Mike Polark upgrades Abbott Laboratories (NYSE:ABT) from Peer Perform to Outperform and announces $130 price target.

Benzinga Newsdesk

PRO
UBS Maintains Buy on Abbott Laboratories, Lowers Price Target to $125

UBS analyst Patrick Wood maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $135 to $125.

Benzinga Newsdesk